Literature DB >> 17704403

End points in advanced colon cancer clinical trials: a review and proposal.

Carmen Allegra1, Charles Blanke, Marc Buyse, Richard Goldberg, Axel Grothey, Neal J Meropol, Leonard Saltz, Alan Venook, Greg Yothers, Daniel Sargent.   

Abstract

Entities:  

Mesh：

Year:  2007        PMID： 17704403     DOI： 10.1200/JCO.2007.12.1368

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  16 in total

1.  Tumor status at 12 weeks predicts survival in advanced colorectal cancer: findings from NCCTG N9741.

Authors:  James M Heun; Axel Grothey; Megan E Branda; Richard M Goldberg; Daniel J Sargent
Journal:  Oncologist       Date:  2011-05-31

Review 2.  Biomarkers and surrogate end points--the challenge of statistical validation.

Authors:  Marc Buyse; Daniel J Sargent; Axel Grothey; Alastair Matheson; Aimery de Gramont
Journal:  Nat Rev Clin Oncol       Date:  2010-04-06       Impact factor: 66.675

3.  Design Issues in Randomized Clinical Trials of Maintenance Therapies.

Authors:  Boris Freidlin; Richard F Little; Edward L Korn
Journal:  J Natl Cancer Inst       Date:  2015-08-18       Impact factor: 13.506

Review 4.  Contributions of meta-analyses based on individual patient data to therapeutic progress in colorectal cancer.

Authors:  Marc Buyse
Journal:  Int J Clin Oncol       Date:  2009-04-24       Impact factor: 3.402

5.  PIK3CA mutation is associated with poor survival among patients with metastatic colorectal cancer following anti-EGFR monoclonal antibody therapy: a meta-analysis.

Authors:  Shuangjie Wu; Yu Gan; Xinhai Wang; Jun Liu; Mengjun Li; Yifan Tang
Journal:  J Cancer Res Clin Oncol       Date:  2013-02-24       Impact factor: 4.553

6.  Progression-free survival as a primary endpoint in clinical trials of metastatic colorectal cancer.

Authors:  S Gill; S Berry; J Biagi; C Butts; M Buyse; E Chen; D Jonker; C Mărginean; B Samson; J Stewart; M Thirlwell; R Wong; J A Maroun
Journal:  Curr Oncol       Date:  2011-10       Impact factor: 3.677

7.  Response analysis for multiple symptoms revealed differences between arms of a symptom management trial.

Authors:  Alla Sikorskii; Charles W Given; Mei You; Sangchoon Jeon; Barbara A Given
Journal:  J Clin Epidemiol       Date:  2009-01-04       Impact factor: 6.437

8.  Surrogate endpoints for overall survival in digestive oncology trials: which candidates? A questionnaires survey among clinicians and methodologists.

Authors:  Nicolas Methy; Laurent Bedenne; Franck Bonnetain
Journal:  BMC Cancer       Date:  2010-06-10       Impact factor: 4.430

9.  A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: the AIO KRK 0110 trial/ML22011 trial.

Authors:  Clemens Giessen; Ludwig Fischer von Weikersthal; Axel Hinke; Sebastian Stintzing; Frank Kullmann; Ursula Vehling-Kaiser; Julia Mayerle; Markus Bangerter; Claudio Denzlinger; Markus Sieber; Christian Teschendorf; Jens Freiberg-Richter; Christoph Schulz; Dominik Paul Modest; Nicolas Moosmann; Philipp Aubele; Volker Heinemann
Journal:  BMC Cancer       Date:  2011-08-23       Impact factor: 4.430

10.  STRATEGIC-1: A multiple-lines, randomized, open-label GERCOR phase III study in patients with unresectable wild-type RAS metastatic colorectal cancer.

Authors:  Benoist Chibaudel; Franck Bonnetain; Christophe Tournigand; Marine Hug de Larauze; Armand de Gramont; Pierre Laurent-Puig; Jérôme Paget; Alexandra Hadengue; Dominique Notelet; Magdalena Benetkiewicz; Thierry André; Aimery de Gramont
Journal:  BMC Cancer       Date:  2015-07-04       Impact factor: 4.430
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.